- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06129409
Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease
A Randomized, Double -Blind (Sponsor-Open), Placebo-Controlled Study to Assess the Effect of NT-0796 on Inflammation in Obese Participants at Risk of Cardiovascular Disease
This trial is a Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled Study to Assess the Effect of NT-0796 on Inflammation in Obese Participants at Risk of Cardiovascular Disease.
Participants will be admitted to an in-patient Clinical Research Unit on Day -1 and will be discharged on Day 30. The trial will include a 7-day out-patient safety follow-up period following the last dose of study treatment.
For the first approximately 20 participants effect of food will be evaluated on the Pharmacokinetics of NT-0796. MRI's will be conducted in a subset of participants.
Study Overview
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: NodThera Ltd.
- Phone Number: 0151 17815230151
- Email: Clinicaltrials@nodthera.com
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33147
- Recruiting
- Investigative Site
-
-
Texas
-
Austin, Texas, United States, 78744
- Recruiting
- Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female aged 18 years or older.
- Body mass index (BMI) ≥30 and ≤40 kg/m2 at screening.
Presence of 1 or more of the following risk factors for atherosclerotic cardiovascular disease:
- History of controlled hypertension
- History of hypercholesterolemia
- History of high-density lipoprotein levels
- Controlled Type 1 or Type 2 Diabetes mellitus
Exclusion Criteria:
- History of stroke with residual neurological deficit within 2 years or transient ischemic attack within 6 months
- History of acute coronary syndrome (ACS)
- Stable angina.
- Diagnosis of congestive heart failure
- Evidence of past or current infection with Hepatitis B or Hepatitis C
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
BID
|
Orally administered capsules
|
Experimental: NT-0796
BID
|
Orally administered capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in hsCRP levels
Time Frame: Baseline to Day 28
|
Evaluate the effects of NT-0796 on inflammation.
|
Baseline to Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Body weight (kg)
Time Frame: Change from baseline to Day 28
|
Change from baseline to Day 28
|
|
Body composition
Time Frame: Change from baseline to Day 28
|
Absolute Fat mass, % Body Fat and Visceral Fat (L)
|
Change from baseline to Day 28
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical laboratory values
Time Frame: Change from baseline to Day 28
|
Haematology and Clinical Chemistry
|
Change from baseline to Day 28
|
Vital signs
Time Frame: Change from baseline to Day 28
|
Body temperature, heart rate and systolic and diastolic blood pressure
|
Change from baseline to Day 28
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NT-0796-P003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
Nanjing Medical UniversityRecruiting
-
Centre Hospitalier Universitaire de la RéunionRecruitingCardiovascular DiseaseFrance
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
Clinical Trials on NT-0796
-
Zimmer Orthobiologics, Inc.UnknownDefect of Articular Cartilage | Osteochondritis Dissecans | Osteochondral Lesion of TalusUnited States
-
Kocaeli UniversityCompletedNasotracheal IntubationTurkey
-
Zimmer Orthobiologics, Inc.UnknownDegenerative Lesion of Articular Cartilage of Knee | Osteochondritis DissecansUnited States
-
Neurotech PharmaceuticalsCompletedMacular Telangiectasia Type 2United States, Australia, Germany
-
Neurotech PharmaceuticalsCompletedA Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol AMacular Telangiectasia Type 2United States, United Kingdom, Australia, France
-
Nidek Co. LTD.CompletedIOP Ranges(mmHg): 7 to 16, >16 to <23, and 23 or MoreJapan
-
PT Kalbe Genexine BiologicsGenexine, Inc.Recruiting
-
Sohag UniversityNot yet recruiting
-
Neurotech PharmaceuticalsCompletedRetinitis PigmentosaUnited States
-
Jeffrey L GoldbergCompletedIschemic Optic Neuropathy/Optic Nerve StrokeUnited States